Maria Pinzon-Ortiz - Concepedia

Author

Maria Pinzon-Ortiz

Novartis (United States)

Also Known As

M Pinzon-Ortiz, M. Consuelo Pinzon-Ortiz, Maria C. Pinzon-Ortiz, Maria Pinzon-Ortiz

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Massachusetts General Hospital Brigham and Women's Hospital Harvard University Dana-Farber Cancer Institute

About

Maria Pinzon-Ortiz is an author at Novartis (United States) specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	688
2	Cell Biology	4	4	538
3	Biochemistry	1	1	12
4	Cellular Physiology	1	1	12
5	Cellular Therapies	1	1	67

Maria Pinzon-Ortiz

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation Gwendolyn T. Wong, Denise Manfra, Frederique M. Poulet, Journal of Biological Chemistry	2004	715
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors Sadhna Vora, Dejan Juric, Nayoon Kim, Cancer Cell Pi3k InhibitorsBreast OncologyMedicineReceptor Tyrosine KinaseBreast Cancer	2014	428
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models Jeffrey L. Brown, Zhe Cao, Maria Pinzon-Ortiz, Molecular Cancer Therapeutics ImmunologyVegf InhibitorsTumor BiologyTumor AngiogenesisAngiogenesis	2010	150
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models Sunkyu Kim, Ralph Tiedt, Alice Loo, Oncotarget	2018	88
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade Kartik Sehgal, Andrew Portell, Elena V. Ivanova, Journal of Clinical Investigation Cell TherapyPd-1 BlockadeImmunologyImmune RegulationImmunoediting	2020	67
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth Beat Nyfeler, Yan Chen, Xiaoyan Li, PLoS ONE Systems BiologyInhibit Mtor SignalingNovel TherapyMedicineTumor Growth	2012	31
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms Raajit K. Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, Clinical Cancer Research	2021	19
Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: Role for p38 kinase Laura Engstrom, Maria Pinzon-Ortiz, Ying Li, International Immunopharmacology Signal TransductionSignaling PathwayBiochemistryG Protein-coupled ReceptorP38 Kinase	2009	12
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one Andreas Lundqvist, Vincent van Hoef, Xiaonan Zhang, Journal for ImmunoTherapy of Cancer	2016	11

Page 1